Patents by Inventor Philip R. Johnson
Philip R. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059744Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. The stalk portion may comprise a variant Fe domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.Type: ApplicationFiled: July 25, 2023Publication date: February 22, 2024Inventors: Bruce C. Schnepp, Philip R. Johnson, James I. Andorko
-
Patent number: 11766490Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: GrantFiled: July 1, 2021Date of Patent: September 26, 2023Assignee: Intergalactic Therapeutics, Inc.Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Patent number: 11767366Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.Type: GrantFiled: December 15, 2022Date of Patent: September 26, 2023Assignee: INTERIUS BIOTHERAPEUTICS, INC.Inventors: Ronnie M. Russell, Philip R. Johnson
-
Publication number: 20230295332Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.Type: ApplicationFiled: December 15, 2022Publication date: September 21, 2023Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
-
Publication number: 20230279363Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.Type: ApplicationFiled: January 20, 2023Publication date: September 7, 2023Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
-
Publication number: 20230270888Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: April 27, 2023Publication date: August 31, 2023Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Patent number: 11684680Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: GrantFiled: November 18, 2022Date of Patent: June 27, 2023Assignee: INTERGALACTIC THERAPEUTICS, INC.Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20230089543Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: November 18, 2022Publication date: March 23, 2023Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Patent number: 11602569Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: GrantFiled: February 18, 2022Date of Patent: March 14, 2023Assignee: Intergalactic Therapeutics, Inc.Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20220168451Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: February 18, 2022Publication date: June 2, 2022Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Patent number: 11324839Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: GrantFiled: July 1, 2021Date of Patent: May 10, 2022Assignee: Intergalactic Therapeutics, Inc. bInventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20210330817Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: July 1, 2021Publication date: October 28, 2021Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20210322576Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: July 1, 2021Publication date: October 21, 2021Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20210322579Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: July 1, 2021Publication date: October 21, 2021Inventors: Bruce C. Schnepp, Philip R. Johnson
-
Publication number: 20210155938Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.Type: ApplicationFiled: April 17, 2019Publication date: May 27, 2021Inventors: Philip R. JOHNSON, Bruce C. SCHNEPP, Jean BENNETT, Scott J. DOOLEY, Krishna Jawaharlal FISHER, Junwei SUN
-
Publication number: 20210002667Abstract: Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.Type: ApplicationFiled: March 15, 2019Publication date: January 7, 2021Inventors: Bruce C. SCHNEPP, Philip R. JOHNSON
-
Patent number: 10645916Abstract: A spray boom includes a body having a length defined between a first end and a second end thereof. The body is formed by a plurality of layers of composite material adapted to be molded together to form an inner surface and an outer surface. An internal cavity is defined in the body internally of the inner surface. A light-emitting system is integrally formed in the body in an outer layer thereof or at a location between the inner surface and the outer surface. The light-emitting downsystem has an on state and an off state in which it is adapted to emit a light when in the on state.Type: GrantFiled: October 4, 2017Date of Patent: May 12, 2020Assignee: DEERE & COMPANYInventors: Patrick M. Murphy, Philip R. Johnson
-
Publication number: 20190098888Abstract: A spray boom includes a body having a length defined between a first end and a second end thereof. The body is formed by a plurality of layers of composite material adapted to be molded together to form an inner surface and an outer surface. An internal cavity is defined in the body internally of the inner surface. A light-emitting system is integrally formed in the body in an outer layer thereof or at a location between the inner surface and the outer surface. The light-emitting system has an on state and an off state in which it is adapted to emit a light when in the on state.Type: ApplicationFiled: October 4, 2017Publication date: April 4, 2019Inventors: Patrick M. Murphy, Philip R. Johnson
-
Publication number: 20150044170Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.Type: ApplicationFiled: April 9, 2014Publication date: February 12, 2015Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Philip R. Johnson, JR., Kelly Reed Clark
-
Patent number: 8486420Abstract: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the same to a subject.Type: GrantFiled: February 15, 2006Date of Patent: July 16, 2013Assignees: The University of North Carolina at Chapel Hill, Children's Hospital, Inc.Inventors: Robert E. Johnston, Philip R. Johnson, Christy K. Jurgens, Kelly Young Poe